Provided by Tiger Trade Technology Pte. Ltd.

Ecopetrol SA

17.75
-0.3200-1.77%
Post-market: 17.920.1677+0.94%19:30 EDT
Volume:1.07M
Turnover:19.00M
Market Cap:36.49B
PE:9.33
High:18.07
Open:17.89
Low:17.54
Close:18.07
52wk High:18.19
52wk Low:8.57
Shares:2.06B
Float Shares:237.00M
Volume Ratio:0.71
T/O Rate:0.45%
Dividend:0.99
Dividend Rate:5.58%
EPS(TTM):1.90
EPS(LYR):1.16
ROE:15.95%
ROA:7.31%
PB:1.78
PE(LYR):15.24

Loading ...

EU scrutiny of Anglo-MMG nickel deal tests China stance

Mining
·
Sep 11

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

GlobeNewswire
·
Sep 10

MMG faces EU antitrust warning over Anglo nickel deal

Mining
·
Sep 08

Press Release: Ecopetrol Announces Changes in Senior Management

Dow Jones
·
Sep 01

Press Release: Ecopetrol Announces Changes in Senior Management

Dow Jones
·
Aug 28

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

GlobeNewswire
·
Aug 24

EC Healthcare shareholders unanimously back AGM resolutions

TIPRANKS
·
Aug 21

Press Release: Ecopetrol Completes Acquisition of a Controlling 51% Stake in Brava Energia S.A. and Strengthens Its Growth Platform in Brazil

Dow Jones
·
Aug 18

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

GlobeNewswire
·
Aug 17

UBS Adjusts Ecopetrol Price Target to $16 From $14, Maintains Neutral Rating

MT Newswires Live
·
Aug 14

UBS Sticks to Their Hold Rating for Ecopetrol SA (EC)

TIPRANKS
·
Aug 14

Press Release: Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Dow Jones
·
Aug 13

City Developments' Patmi triples in 1HFY2026; strategic review by end of Sept

The Edge Singapore
·
Aug 12

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

GlobeNewswire
·
Aug 11

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

GlobeNewswire
·
Aug 05

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

GlobeNewswire
·
Aug 04

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

GlobeNewswire
·
Aug 04

Karyopharm down 69% after XPORT-EC-042 trial did not meet primary endpoint

TIPRANKS
·
Jul 31

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
Jul 30

Press Release: Pharming Reports Second Quarter and First Half 2026 Financial Results and Revises Year-end Guidance; Strong Joenja Momentum and Near-term Clinical Readouts to Support Broader Therapeutic Use

Dow Jones
·
Jul 30